ENTXHealthcare · BiotechnologyThe 1 Wall Street analysts covering Entera Bio Ltd. hold a median 12-month price target of $9 — +211.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 15 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Entera Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (76): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ENTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +211.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $9.00 |
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Dec 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Sept 2022 | HC Wainwright & Co. | Initiates | Buy | — |
| 19 July 2022 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENTX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 1% of US stocks
Cheaper than 5% of US stocks
Cheaper than 92% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Entera Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Entera Bio has reached an agreement with the FDA on a 12-month, placebo-controlled registrational trial design for its oral osteoporosis drug candidate EB613, and plans to begin a Phase 3 study.
Why it matters — The FDA agreement clears a key regulatory path for EB613, moving Entera Bio's lead candidate closer to potential approval in the osteoporosis space.
Entera Bio Ltd. announced its second quarter 2026 financial results and reported that the FDA has aligned on a 12-month registrational Phase 3 study design to support a New Drug Application for EB613, the first oral anabolic tablet in development for postmenopausal women with osteoporosis.
Why it matters — FDA agreement on a Phase 3 registrational study for EB613 brings Entera's lead candidate one step closer to a potential NDA submission, marking a significant clinical and regulatory milestone for the company.
Entera Bio announced that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34) tablet) has been selected for two presentations, including the Plenary Poster Presentation, at the ASBMR 2026 Annual Meeting in Boston.
Why it matters — The selection of Entera's data for a plenary poster session at a major scientific conference highlights recognition of EB613's potential as an oral anabolic treatment for osteoporosis.
Entera Bio Ltd. announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference.
Why it matters — The company's participation in a major investor conference provides visibility for its oral peptide development programs among the financial community.
Global law firm Greenberg Traurig advised Entera Bio Ltd. in a record $275 million PIPE for an Israeli biotech company.
Why it matters — A $275 million PIPE represents a significant capital infusion for Entera Bio, marking a record financing event for an Israeli biotech.
The 1 Wall Street analysts covering Entera Bio Ltd. have a median 12-month price target of $9, with estimates ranging from $9 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Entera Bio Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Entera Bio Ltd. 46 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Entera Bio Ltd. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (76 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +211.4% from the last close, and Ticker Nerd's factor model ranks Entera Bio Ltd. 46 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Entera Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $9 over the next 12 months.
Entera Bio Ltd. returned +46.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focusing on oral delivery solutions for large molecules, which traditionally require injection.
The most recent item we track (MarketBeat, 13 Aug 2026): "Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement". Entera Bio has reached an agreement with the FDA on a 12-month, placebo-controlled registrational trial design for its oral osteoporosis drug candidate EB613, and plans to begin a Phase 3 study.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focusing on oral delivery solutions for large molecules, which traditionally require injection. The company's primary endeavor is to develop orally administered therapeutics aimed at unmet medical needs, with a notable emphasis on hormone therapeutics and biologics. By leveraging proprietary technology platforms, Entera Bio seeks to transform the way medical treatments are administered, particularly in the fields of osteoporosis and hypoparathyroidism. Entera’s innovative approach has potentially broad applications across numerous therapeutic fields that rely on biological treatments, which typically face challenges in oral administration. In the financial markets, Entera Bio Ltd. represents a pioneering player within the biotech sphere, driving advancements in drug delivery systems. Its commitment to addressing significant pharmaceutical challenges places it at the forefront of a crucial transformation in drug therapy delivery methods, potentially impacting patient adherence and overall treatment efficacy in significant ways.
CEO Ms. Miranda J. Toledano M.B.A. · 20 employees · Israel · https://enterabio.com